Australian scientists have developed a hi-tech handheld 'bio pen' that can enable surgeons to draw new bone material onto seriously injured people.
The 'bio pen' contains stem cells and growth factors, and could eliminate the need to harvest cartilage and grow it for weeks in a lab.
The pen-like device developed at the University of Wollongong (UOW) will allow surgeons to design customised implants on-site and at the time of surgery.
The BioPen will give surgeons greater control over where the materials are deposited while also reducing the time the patient is in surgery by delivering live cells and growth factors directly to the site of injury, accelerating the regeneration of functional bone and cartilage, scientists say.
The BioPen works similar to 3D printing methods by delivering cell material inside a bio-polymer such as alginate, a seaweed extract, protected by a second, outer layer of gel material.
The two layers of gel are combined in the pen head as it is extruded onto the bone surface and the surgeon 'draws' with the ink to fill in the damaged bone section.
A low powered ultra-violet light source is fixed to the device that solidifies the inks during dispensing, providing protection for the embedded cells while they are built up layer-by-layer to construct a 3D scaffold in the wound site.
Once the cells are 'drawn' onto the surgery site they will multiply, become differentiated into nerve cells, muscle cells or bone cells and will eventually turn from individual cells into a thriving community of cells in the form of a functioning a tissue, such as nerves, or a muscle.
The device can also be seeded with growth factors or other drugs to assist regrowth and recovery, while the hand-held design allows for precision in theatre and ease of transportation.
The BioPen prototype was designed and built using the 3D printing equipment in the labs at Wollongong and was handed over to clinical partners at St Vincent's Hospital Melbourne, led by Professor Peter Choong, who will work on optimising the cell material for use in clinical trials.
The BioPen will help build on recent work by researchers where they were able to grow